Company Filing History:
1 out of 8 
1 out of 1 
1 out of 2 Years Active: 2022-2025
Title: Innovations of Shuya Wang in Coagulation Factor VIII Fusion Proteins
Introduction
Shuya Wang is a notable inventor based in Kaifeng, China, recognized for his contributions to the field of biopharmaceuticals. He holds 2 patents that focus on advancements in coagulation factor VIII fusion proteins, which are crucial for treating blood clotting disorders.
Latest Patents
His latest patents include "FVIII fusion protein and use thereof," which discloses a coagulation factor VIII fusion protein conjugated with polyalkylene glycol, significantly increasing its half-life compared to traditional methods. The invention details a preparation method and application, emphasizing the direct or indirect linkage of the active moiety to a fusion partner. Another significant patent is "Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same." This patent describes a highly glycosylated FVIII fusion protein that maintains biological activity similar to recombinant FVIII while extending its in vivo half-life, thereby enhancing pharmacokinetics and drug efficacy.
Career Highlights
Shuya Wang has worked with prominent companies in the biopharmaceutical sector, including Ampsource Biopharma Shanghai Inc. and Furen Pharmaceutical Group Co., Ltd. His work has significantly impacted the development of therapies for hemophilia and other blood-related conditions.
Collaborations
He has collaborated with notable colleagues such as Zijia Ren and Wenwen Wang, contributing to the advancement of research in his field.
Conclusion
Shuya Wang's innovative work in coagulation factor VIII fusion proteins showcases his commitment to improving treatment options for patients with blood clotting disorders. His patents reflect significant advancements in biopharmaceutical technology, enhancing the efficacy and safety of therapies.